The success of the Human Genome Project in 2003 led to the launch of the Human Microbiome Project, which envisages mapping the microbial diversity that exists inside the human body. Just as the case with the Human Genome Project, the Microbiome project has important implications with respect to the pharmaceutical industry.
The human microbiome is still an emerging field and focuses on the more than trillions of bacteria that live in our bodies. The important thing to know is that there is a mix of good and bad bacteria, which is very significantly linked to the way diseases are studied and treated.
An academic field is deemed to become a major marvel when the pharmaceutical sector decides to invest in it. Just last month, Johnson and Johnson made a major investment along with Second Genome (Biotech Company) to focus on the human microbiome. The idea is that the companies can look at drug targets that work by modifying the kind of bacteria that lives inside our gut. This can result in breakthrough drugs for a number of painful ulcers and even liver [Read more…]